English

Guangzhou daifen Biotech Co.,Ltd

This is a verified supplier can provide quality products and have passed the Business License Check.

Home > Products > Local Anesthetic Drugs > 99% USP Pain Killer Drug Lidocaine Base Raw Powder Drug CAS 137-58-6
 

99% USP Pain Killer Drug Lidocaine Base Raw Powder Drug CAS 137-58-6

  • 99% USP Pain Killer Drug Lidocaine Base Raw Powder Drug CAS 137-58-6
Place of Origin:
China
Brand Name:
Kafen
Certification:
GMP
Model Number:

137-58-6

Min.Order Quantity:
10g
Price:
Negotiable
Packaging Details:
Discreet and disguised
Delivery Time:
Within 24 hours after receiving your payment
Payment Terms:
Western Union, MoneyGram,Bitcoin and Bank Transfer
Supply Ability:
5000KG/Month
Contact Now
 

Product Description

Product Name:Lidocaine Base

CAS No.: 137-58-6
Molecular formula: C14H22N2O
Formula weight: 234.34
EINECS No.: 205-302-8
Melting point: 66-69°C
Flash point: 9ºC
Storage: Refrigerator
Stability: Stable. Incompatible with strong oxidizing agent.

 

Product Description:

Lidocaine, xylocaine, or lignocaine is a common local anesthetic and class-1b antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning, and pain from skin inflammations, injected as a dental anesthetic, or as a local anesthetic for minor surgery.It is on the World Health Organizations List of Essential Medicines, a list of the most important medications needed in a basic healthcare system.

Lidocaine is the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine prophylactic administration is no longer recommended for acute cardiac infarction; the overall benefit of this measure is not convincing.

Product Applications:

The efficacy profile of lidocaine as a local anesthetic is characterized by a rapid onset of action and intermediate duration of efficacy. Therefore, lidocaine is suitable for infiltration, block, and surface anesthesia. Longer-acting substances such as bupivacaine are sometimes given preference for subdural and epidural anesthesias; lidocaine, though, has the advantage of a rapid onset of action.

Epinephrine vasoconstricts arteries, reducing bleeding and also delays the resorption of lidocaine, almost doubling the duration of anaesthesia. For surface anesthesia, several available formulations can be used e.g. for endoscopies, before intubations, etc. Buffering the pH of lidocaine makes local freezing less painful. Lidocaine drops can be used on the eyes for short ophthalmic procedures.

Relative insensitivity to lidocaine is genetic. In hypokalemic sensory overstimulation, relative insensitivity to lidocaine has been described in people who also have attention deficit hyperactivity disorder.In dental anesthesia, a relative insensitivity to lidocaine can occur for anatomical reasons due to unexpected positions of nerves. Some people with Ehlers-Danlos syndrome are insensitive to lidocaine.

Lidocaine, along with ethanol, ammonia, and acetic acid, has also been proven to be effective in treating jellyfish stings, both numbing the affected area and preventing further nematocyst discharge

Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion.
Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of Lidocaine. Approximately 90% of Lidocaine administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline.

 

Items Tested Specification BP2007 Result
Characters White or slightly yellow crystal powder with characteristic odor White crystal powder with weak odor
Melting point Melting point: 66 degree to 70 degree 66.6 degree-68.5 degree
Identification BCDE
Comply with the requirement
Conforms
Appearance of solution Clear and colorless Conforms
Water Not more than 0.5% 0.3%
Sulphate Not more than0. 1% Conforms
Chloride Not more than 0. 0035% 0.0025%
Heavy Metals Not more than 0.002% 0.001%
Residue on Ignition Not more than 0.1% 0.02%
Impurity
(26-dimethylaniline content)
Not more than 0.01% Conforms
Assay (HPLC) 99.0%-101.0% 99.50%

 

 


99% USP Pain Killer Drug Lidocaine Base Raw Powder Drug CAS 137-58-6 Images

 

Send Inquiry

*Email

Please Enter your Email Address

Subject

Inquiry About

Quick question
Please select FAQ

I'm very interested in your products; could you send me some detail reference information?

Please send me detail product specification, thank you!

May I be an agency of your products,and what's yourterms?

We intend to purchase this product, would you please send me the quotation and minimum order quantity?

*Message
I want to buy

For the best results, we recommend including the following details: -Self introduction -Required specifications -Inquire about price/MOQ